MagForce Nanotechnologies AG to Present at Deutsches Eigenkapitalforum
(Thomson Reuters ONE) -
MagForce Nanotechnologies AG /
MagForce Nanotechnologies AG to Present at Deutsches Eigenkapitalforum
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
Berlin, November 18, 2010 - MagForce Nanotechnologies AG (FSE:MF6), a leader in
the area of nanotechnology-based cancer treatment, announced today that Dr.
Peter Heinrich, CEO, will present the latest company developments and outline
plans for 2011 at the Deutsches Eigenkapitalforum. The presentation will take
place on Tuesday, November 23, 2010, at 8:15 in Sector Technology (Paris Room).
Earlier this year, MagForce received EU approval for its medical products,
NanoTherm(®) and NanoActivator(TM), for the treatment of brain tumors. The
company plans to launch its Nano-Cancer(®) therapy at leading cancer centers in
Germany in the first quarter of 2011.
ABOUT MAGFORCE NANOTECHNOLOGIES:
MagForce Nanotechnologies AG is a leader in the area of nanotechnology-based
cancer treatment and the first company worldwide to receive European approval
for a medical product using nanoparticles. Its proprietary procedure, Nano-
Cancer(®) therapy, enables the targeted treatment of solid tumors through the
intratumoral release of heat from magnetic nanoparticles. The company's
products, Nanotherm(®), NanoPlan(®), and NanoActivator(TM) are the components of
its Nano-Cancer(®) therapy.
DISCLAIMER:
This release may contain forward-looking statements and information which may be
identified by formulations using terms such as "expects," "aims," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates," or "will". Such forward-
looking statements are based on our current expectations and certain assumptions
which may be subject to a variety of risks and uncertainties. The results
actually achieved by MagForce Nanotechnologies AG may substantially differ from
these forward-looking statements. MagForce Nanotechnologies AG assumes no
obligation to update these forward-looking statements or to correct them in case
of developments which differ from those anticipated. MagForce, Nanotherm,
NanoActivator and Nano-Cancer are trademarks of MagForce Nanotechnologies AG in
selected countries.
For questions, please contact:
Stacy Wiedenmann
Director, Investor Relations & Corporate Communications
Magforce Nanotechnologies AG
Max-Dohrn-Str. 8
10589 Berlin
T +49 30 308 380 31
F +49 30 308 380 99
M +49 151 12000 722
email:swiedenmann(at)magforce.com
www.magforce.com
[HUG#1463954]
--- End of Message ---
MagForce Nanotechnologies AG
Max-Dohrn-Str. 8 Berlin Germany
Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MagForce Nanotechnologies AG via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2010 - 17:48 Uhr
Sprache: Deutsch
News-ID 48918
Anzahl Zeichen: 3586
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MagForce Nanotechnologies AG to Present at Deutsches Eigenkapitalforum"
steht unter der journalistisch-redaktionellen Verantwortung von
MagForce Nanotechnologies AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
